Status:
COMPLETED
Prevalence+Significance of Paraneoplastic Autoantibodies in Many Cancers
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Lung Cancer
Ovarian Cancer
Eligibility:
All Genders
Brief Summary
You may have a type of cancer associated with "antineuronal antibodies" in your blood. Antibodies are substances made by the immune system. They are used by the body to fight infections and other dis...
Detailed Description
Objectives: To determine prospectively the prevalence and specificity of anti-Hu and other paraneoplastic antibodies in patients with small cell lung cancer (SCLC) and other cancers including, but no...
Eligibility Criteria
Inclusion
- Patients with previous cancers or concurrent cancers. Patient has or may have, newly-diagnosed or recurrent SCLC, or mixed small cell/non small cell lung cancer, or neuroblastoma, or ovarian or breast cancer, or Hodgkin's disease in all cases confirmed by pathological review.
Exclusion
- Patient refusal to participate in follow-up clinical evaluations. For minors, parental or guardian refusal.
- Patient refusal to provide blood samples for autoantibody determinations and HLA typing (total 4 tubes).
Key Trial Info
Start Date :
July 1 1995
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2009
Estimated Enrollment :
121 Patients enrolled
Trial Details
Trial ID
NCT00608452
Start Date
July 1 1995
End Date
November 1 2009
Last Update
November 13 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065